Monarch Fund Protects Key Areas in the Monarch Butterfly Biosphere

Gabriel Holschneider serves as chairman and CEO of the Rainmaker Group, a consulting company in Mexico City that focuses on risk management. Aside from his professional responsibilities, Gabriel Holschneider serves on the Board of Directors of the Mexican Fund for the Conservation of Nature, or Fondo Mexicano para la Conservacion de la Naturaleza (FMCN).

One of the largest and most effective environmental funds in Latin America, FMCN is dedicated to fighting for the preservation of natural areas within Mexico. A key initiative for the group is the Monarch Fund, a permanent project that works to promote the conservation and protection of wilderness areas within the Monarch Butterfly Biosphere Reserve.

Each year, millions of the iconic orange-and-black butterflies make a 4,800-kilometer journey from Canada all the way to their winter sanctuaries in Mexico. Using the sun to navigate, the butterflies spend eight months crossing the continent. Once they arrive, large clusters of monarchs rest together high in the trees within an area of about 56,000 hectares, approximately 100 kilometers northwest of Mexico City. 

In an effort to conserve and protect the Monarch Butterfly Biosphere Reserve, FMCN actively works to raise funds that support efforts toward environmental education, restoration, forest fire protection, and community involvement.

Boston Children's Hospital Pioneering Hydrocephalus Program

Attorney Gabriel Holschneider is the chief executive officer of the Rainmaker Group. An active environmental advocate, Mr. Holschneider is a supporter of Fondo Mexicano para la Conservacion de la Naturaleza (Mexican Fund for the Conservation of Nature), a major nonprofit organization based in Latin America. In addition, Gabriel Holschneider contributes to Boston Children’s Hospital.

Through the years, Boston Children’s Hospital has served as a trailblazer for numerous breakthroughs in pediatrics. The hospital is credited as the first in history to successfully treat hydrocephalus via shunting - a process that reroutes excess fluid from the brain into another body cavity.

Sixty years later, Boston Children’s hydrocephalus program continues to be an industry leader in treatment. New shunting technologies such as externally programmable shunts have been successfully tested by the hospital. Moreover, the hydrocephalus program has been instrumental in the refinement of minimally invasive surgical techniques, including the landmark ETV/CPC (Endoscopic Third Ventriculostomy with Choroid Plexus Coagulation) procedure.